nach oben

Erschienen in:

01.07.2020 | Clinical study

Axitinib plus avelumab or pembrolizumab: management of AEs

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Clinical monitoring and experience with both axitinib and immune checkpoint inhibitors (ICI) are necessary to manage adverse events (AEs) of axitinib−ICI combination therapy for first-line treatment of advanced renal cell carcinoma (RCC), which has recently been approved by the European Medicines Agemcy (EMA) and the US FDA, say authors of a Merck KGaA- and Pfizer-funded study published in the British Journal of Cancer which included a systematic review. …

Grunwald V, et al. Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. British Journal of Cancer : 26 Jun 2020. Available from: URL: http://doi.org/10.1038/s41416-020-0949-9

Titel: Axitinib plus avelumab or pembrolizumab: management of AEs
Publikationsdatum: 01.07.2020
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-020-80485-5

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Sodium-bicarbonate

Immunosuppressants

Nivolumab

Colecalciferol

Multiple drugs

Bupropion/haloperidol